Rodents with pharmacological inhibition and knockdown of TLR4 as well as neuronal deletion of the TLR adaptor molecule myeloid differentiation primary response 88 (MyD88) are protected from HFD-induced leptin resistance and metabolic disorders [34,35,37,38]. This evidence concerns the gene TLR4 and metabolic disease.